Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilrekimig in Moderate-to-Severe COPD
NCT07839884Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Sep 2026
- Primary completion
- May 2034
01
Overview
Phase 3, open-label, single-arm trial of tilrekimig in chronic obstructive pulmonary disease (COPD), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events at 60 weeks, Number of Participants With Treatment-Emergent Serious Adverse Events at 60 weeks and 2 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
tilrekimig
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07839884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07839884.